In recent years, some FXR antagonists have displayed beneficial effects in cholestasis [8] and hypercholesterolemia [9] animal models, suggesting that FXR antagonists may be worth pursuit in this context. This evidence concerns the gene NR1H4 and Hypercholesterolemia.